or Try an Advanced Search...

    Technical Analysis for CERO - CERo Therapeutics Holdings, Inc.

    Grade Last Price % Change Price Change
    F 0.25 -5.54% -0.01
    CERO closed down 5.54 percent on Wednesday, July 3, 2024, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical CERO trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    Spinning Top Other 0.00%
    Narrow Range Bar Range Contraction 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -5.54%
    NR7 Range Contraction -5.54%
    Older End-of-Day Signals for CERO ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 8 hours ago
    2x Volume Pace about 12 hours ago
    1.5x Volume Pace about 12 hours ago
    Down 5% about 12 hours ago
    Down 3% about 12 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    CERO Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    CERo Therapeutics Holdings, Inc. Description

    CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T"). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2024 for hematological malignancies.

    Classification
    Sector: Other
    Industry: Other
    Keywords: Cancer Solid Tumors Immune System Immunotherapy Treatment Of Cancer Tumor Cancer Immunotherapy Cell Therapy Lymphoma Virotherapy Hematological Malignancies Adoptive Cell Transfer T Cells Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Therapy Car T Cell Treating Cancer

    Is CERO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 13 CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
    Jun 6 Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy
    Jun 6 CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
    May 15 CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
    Apr 30 CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes
    Apr 10 CERo Therapeutics files to sell 26.62M shares of common stock
    Mar 20 Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
    Mar 11 Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
    Mar 7 Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Mar 7 CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
    See more CERO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.8
    52 Week Low 0.2432
    Average Volume 1,207,229
    200-Day Moving Average 7.05
    50-Day Moving Average 1.11
    20-Day Moving Average 0.45
    10-Day Moving Average 0.30
    Average True Range 0.11
    RSI (14) 17.36
    ADX 27.2
    +DI 16.49
    -DI 31.79
    Chandelier Exit (Long, 3 ATRs) 0.69
    Chandelier Exit (Short, 3 ATRs) 0.57
    Upper Bollinger Bands 0.86
    Lower Bollinger Band 0.03
    Percent B (%b) 0.27
    BandWidth 187.70
    MACD Line -0.27
    MACD Signal Line -0.31
    MACD Histogram 0.0369
    Fundamentals Value
    Market Cap 1.58 Million
    Num Shares 6.23 Million
    EPS -0.35
    Price-to-Earnings (P/E) Ratio -0.73
    Price-to-Sales 0.00
    Price-to-Book 123.73
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.29
    Resistance 3 (R3) 0.29 0.28 0.29
    Resistance 2 (R2) 0.28 0.27 0.28 0.29
    Resistance 1 (R1) 0.27 0.27 0.26 0.27 0.28
    Pivot Point 0.26 0.26 0.25 0.26 0.26
    Support 1 (S1) 0.24 0.25 0.24 0.24 0.23
    Support 2 (S2) 0.23 0.24 0.23 0.22
    Support 3 (S3) 0.21 0.23 0.22
    Support 4 (S4) 0.21